COMPARISON
Teriparatide vs Vosoritide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Teriparatide is authorised or registered in 10 and Vosoritide in 7 of the 10 registers read. Teriparatide: highest phase Phase 4 (after approval). Vosoritide: highest phase Phase 3 (3 phase 3 trials, 0 with posted results). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Teriparatide | Vosoritide | |
|---|---|---|
| Registered trials differs | 185 clinicaltrials.gov · 2026-10-03 | 23 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: teriparatide openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VOXZOGO 0.4mg openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2003-06-10 ema · 2026-10-03 | 2021-08-26 ema · 2026-10-03 |
| EU withdrawn on differs | 2020-11-24 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for vosoritide |
| ATC code differs | H05AA02 ema · 2026-10-03 | M05BX ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Teriparatide | placebo | Vosoritide | placebo |
|---|---|---|---|---|
| Constipation | 5.3% | 4.5% | 11.6% | 6.3% |
| Nasopharyngitis | 14.1% | 13.4% | - | - |
| Hypercalciuria | 11.3% | 6.7% | - | - |
| Back pain | 9.5% | 10.2% | - | - |
| Arthralgia | 9.1% | 9.2% | - | - |
| Headache | 7.6% | 6.5% | - | - |
| Upper respiratory tract infection | 7.0% | 5.6% | - | - |
| Dizziness | 6.8% | 5.2% | - | - |
| Nausea | 6.3% | 3.8% | - | - |
| Pain in extremity | 6.0% | 5.2% | - | - |
| Injection site reaction | - | - | 79.1% | 40.6% |
| Injection site erythema | - | - | 76.7% | 40.6% |
| Viral infection | - | - | 18.6% | 12.5% |
| Injection site swelling | - | - | 18.6% | 6.3% |
| Fall | - | - | 16.3% | 9.4% |
| Injection site urticaria | - | - | 14.0% | 3.1% |
| Arthropod bite | - | - | 14.0% | 6.3% |
| Injection site induration | - | - | 11.6% | 0.0% |
| Rhinitis | - | - | 9.3% | 0.0% |
Trial register Teriparatide: 11 placebo-controlled trials; Vosoritide: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Teriparatide side effects · Vosoritide side effects
LEGAL STATUS
Approval in each country read
| Country | Teriparatide | Vosoritide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.